Raffaele Ratta

1.2k total citations
65 papers, 602 citations indexed

About

Raffaele Ratta is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Raffaele Ratta has authored 65 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Raffaele Ratta's work include Renal cell carcinoma treatment (32 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Prostate Cancer Treatment and Research (21 papers). Raffaele Ratta is often cited by papers focused on Renal cell carcinoma treatment (32 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Prostate Cancer Treatment and Research (21 papers). Raffaele Ratta collaborates with scholars based in Italy, France and United States. Raffaele Ratta's co-authors include Giuseppe Procopio, Elena Verzoni, Paolo Grassi, Filippo de Braud, Alessia Mennitto, Philippe Beuzeboc, Florian Scotté, Mélanie Claps, Pierangela Sepe and Michele Prisciandaro and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Raffaele Ratta

62 papers receiving 594 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raffaele Ratta Italy	17	435	327	197	185	82	65	602
Vincenzo Emanuele Chiurì Italy	12	456 1.0×	478 1.5×	213 1.1×	189 1.0×	67 0.8×	35	703
Daniel Lee South Korea	12	631 1.5×	519 1.6×	197 1.0×	100 0.5×	47 0.6×	35	850
Brenda Dickow United States	11	280 0.6×	215 0.7×	162 0.8×	94 0.5×	57 0.7×	20	449
Bogdan Żurawski United States	15	534 1.2×	528 1.6×	157 0.8×	147 0.8×	66 0.8×	37	773
I. Alex Bowman United States	14	423 1.0×	235 0.7×	206 1.0×	141 0.8×	164 2.0×	40	610
Émeline Colomba France	12	245 0.6×	307 0.9×	216 1.1×	98 0.5×	75 0.9×	71	526
Kuniko Sunami Japan	16	297 0.7×	320 1.0×	150 0.8×	196 1.1×	47 0.6×	47	638
Tom Waddell United Kingdom	7	567 1.3×	427 1.3×	269 1.4×	207 1.1×	131 1.6×	18	715
Laure Hirsch France	9	246 0.6×	297 0.9×	183 0.9×	116 0.6×	45 0.5×	16	517
Marco Angelo Burgio Italy	15	513 1.2×	676 2.1×	152 0.8×	115 0.6×	63 0.8×	44	883

Countries citing papers authored by Raffaele Ratta

Since Specialization

Citations

This map shows the geographic impact of Raffaele Ratta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raffaele Ratta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raffaele Ratta more than expected).

Fields of papers citing papers by Raffaele Ratta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raffaele Ratta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raffaele Ratta. The network helps show where Raffaele Ratta may publish in the future.

Co-authorship network of co-authors of Raffaele Ratta

This figure shows the co-authorship network connecting the top 25 collaborators of Raffaele Ratta. A scholar is included among the top collaborators of Raffaele Ratta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raffaele Ratta. Raffaele Ratta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, Gwénaëlle Gravis, Raffaele Ratta, et al.. (2024). 1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results. Annals of Oncology. 35. S968–S968. 1 indexed citations

Choueiri, Toni K., Laurence Albigès, Philippe Barthélémy, et al.. (2024). Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. The Lancet. 404(10460). 1309–1320. 32 indexed citations

Fizazi, Karim, Alice Bernard‐Tessier, Guilhem Roubaud, et al.. (2023). Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. NEJM Evidence. 3(1). EVIDoa2300171–EVIDoa2300171. 13 indexed citations

Oudard, Stéphane, Raffaele Ratta, Éric Voog, et al.. (2023). 1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial. Annals of Oncology. 34. S978–S979. 1 indexed citations

Auclin, Édouard, Anna Patrikidou, Laura Mezquita, et al.. (2023). Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. Cancers. 15(4). 1066–1066. 10 indexed citations

Petrylak, Daniel P., Raffaele Ratta, Nobuaki Matsubara, et al.. (2023). Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 129–129. 1 indexed citations

Piasecki, Piotr, Chee Goh, Péter Árkosy, et al.. (2023). A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial.. Journal of Clinical Oncology. 41(16_suppl). 5052–5052.

Graff, Julie N., Mauricio Burotto, Peter C.C. Fong, et al.. (2023). 1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study. Annals of Oncology. 34. S957–S957. 13 indexed citations

Vallée, Alexandre, et al.. (2022). Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study. Current Oncology. 29(2). 945–955. 6 indexed citations

10.

Fizazi, Karim, Alice Bernard‐Tessier, Philippe Barthélémy, et al.. (2022). 1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients. Annals of Oncology. 33. S1165–S1165. 2 indexed citations

11.

Rinchai, Darawan, Elena Verzoni, Veronica Huber, et al.. (2021). Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. SHILAP Revista de lepidopterología. 11(6). e434–e434. 5 indexed citations

12.

Petrylak, Daniel P., Raffaele Ratta, Rustem Gafanov, et al.. (2021). KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 17(25). 3291–3299. 32 indexed citations

13.

Epaillard, Nicolas, Yohann Loriot, Pernelle Lavaud, et al.. (2021). Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study. Frontiers in Oncology. 11. 9 indexed citations

14.

Ratta, Raffaele, Annalisa Guida, Florian Scotté, et al.. (2020). PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer and Prostatic Diseases. 23(4). 549–560. 30 indexed citations

15.

Ratta, Raffaele, Elena Verzoni, Alessia Mennitto, et al.. (2020). Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. Tumori Journal. 107(6). 542–549. 7 indexed citations

16.

Petrylak, Daniel P., Neal D. Shore, Mostefa Bennamoun, et al.. (2020). 233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study. Annals of Oncology. 31. S1332–S1333. 1 indexed citations

17.

Raimondi, Alessandra, Raffaele Ratta, Elena Verzoni, et al.. (2019). Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Clinical Genitourinary Cancer. 17(4). 291–298. 24 indexed citations

18.

Verzoni, Elena, Agata Cova, Paola Squarcina, et al.. (2017). Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients. Annals of Oncology. 28. vi17–vi17. 1 indexed citations

19.

Ratta, Raffaele, Paolo Grassi, Elena Verzoni, et al.. (2016). Nivolumab in metastatic renal cell carcinoma (mRCC) patients: a real world single-center experience. Annals of Oncology. 27. iv30–iv30. 2 indexed citations

20.

Ratta, Raffaele, Roberta Zappasodi, Daniele Raggi, et al.. (2016). Immunotherapy advances in uro-genital malignancies. Critical Reviews in Oncology/Hematology. 105. 52–64. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact